Drug Type AAV based gene therapy |
Synonyms |
Target |
Mechanism Nav1.7 modulators(Sodium channel protein type IX alpha subunit modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Erythromelalgia | Preclinical | US | 14 Mar 2024 | |
Small Fiber Neuropathy | Preclinical | US | 14 Mar 2024 |